AGITG Trial news: The AGITG currently has 12 studies open to recruitment and 13 studies in follow up.
The table below details the AGITG trials that are currently accruing patients.
| Recruited | Target | Date of First Site Open (ANZ) | Number of Sites Open | End of Recruitment | |
| ACME ABC (Biliary tract cancer) | 21 | 50-75 | 23 February 2023 | 1 | November 2024 |
| ASCEND (Pancreatic cancer) | 128 | 155 | 13 April 2022 | 23 | April 2024 |
| ICEMELT (Pan Tumour) | 204 | 200 | 9 December 2020 | 2 | November 2025 |
| INTEGRATE IIb (Gastro-oesophageal cancer) | 383 | 450 | 28 April 2021 | 23 | April 2023 |
| MASTERPLAN (Pancreatic cancer) | 44 | 120 | 01 October 2019 | 14 | October 2023 |
| MASTERPLAN Microbiome (Pancreatic cancer) | 10 | 60 | July 2022 | 5 | February 2024 |
| NEO-IMPACT (Pancreatic cancer) | 12 | 20 | 13 May 2022 | 3 | June 2024 |
| OXTOX (Colorectal cancer) | 36 | 100 | 18 December 2020 | 10 | December 2023 |
| PALEO (Oesophageal cancer) | 10 | 54 | 3 December 2021 | 7 | May 2023 |
| RANDOMS (Pancreatic cancer) | 16 | 60 | 14 December 2020 | 3 | February 2024 |
| RENO (Rectal cancer) | 87 | 125 | 21 January 2019 | 10 | January 2024 |
| RESOLUTE (Colorectal Cancer) | 2 | 75 | 14 December 2021 | 9 | December 2024 |
| SPAR (Rectal cancer) | 129 | 222 | 13 April 2018 | 19 | May 2023 |
| VADER (Colorectal cancer) | 1 | 90 | 23 January 2023 | 8 | June 2024 |